Table 2.
Baseline characteristics according to the CPRS
| Variable | Overall (n=30) | Low CPRS (n=22) | High CPRS (n=8) | P-value |
|---|---|---|---|---|
| Age, years | 69.8±8.8 | 69.8±8.7 | 69.8±9.8 | 1.0 |
| Male, n (%) | 20 (67) | 17 (77) | 3 (38) | 0.041 |
| Diabetes mellitus, n (%) | 14 (47) | 9 (41) | 5 (63) | 0.42 |
| Hypertension, n (%) | 29 (97) | 21 (95) | 8 (100) | 1.0 |
| Dyslipidemia, n (%) | 28 (93) | 21 (95) | 7 (88) | 0.47 |
| Chronic kidney disease, n (%) | 16 (53) | 11 (50) | 5 (63) | 0.69 |
| Current smoker, n (%) | 5 (17) | 3 (14) | 2 (25) | 0.59 |
| Family history of coronary artery disease, n (%) | 5 (17) | 4 (18) | 1 (13) | 1.0 |
| History of PCI or CABG, n (%) | 18 (60) | 14 (64) | 4 (50) | 0.68 |
| History of CI or carotid artery stenosis, n (%) | 12 (40) | 10 (45) | 2 (25) | 0.42 |
| Oral medication on admission, n (%) | ||||
| Prior aspirin use | 30 (100) | 22 (100) | 8 (100) | - |
| Prior clopidogrel use | 25 (83) | 18 (82) | 7 (88) | 1.0 |
| Prior prasugrel use | 4 (13) | 3 (14) | 1 (13) | 1.0 |
| Prior beta blocker use | 16 (53) | 11 (50) | 5 (63) | 0.69 |
| Prior ACEI or ARB | 19 (63) | 14 (64) | 5 (63) | 1.0 |
| Prior statin use | 26 (87) | 20 (91) | 6 (75) | 0.28 |
| Laboratory tests | ||||
| Hemoglobin, g/dL | 12.8±1.6 | 13.1±1.5 | 11.9±1.6 | 0.072 |
| White blood cell count, /μL | 6,100 (5,000-7,000) | 6,100 (5,300-7,000) | 5,300 (4,150-6,750) | 0.35 |
| CRP, mg/dL | 0.12 (0.04-0.17) | 0.09 (0.04-0.15) | 0.12 (0.07-1.06) | 0.37 |
| Total protein, g/dL | 7.1 (6.7-7.4) | 7.0 (6.7-7.4) | 7.1 (6.7-7.4) | 0.94 |
| Albumin, g/dL | 4.2 (4.0-4.4) | 4.2 (4.0-4.4) | 4.2 (3.6-4.4) | 0.56 |
| Creatinine, mg/dL | 0.95 (0.84-1.11) | 0.97 (0.84-1.07) | 0.86 (0.78-4.70) | 0.87 |
| eGFR, mL/min | 50.8±22.3 | 54.7±19.6 | 40.1±27.2 | 0.114 |
| Calcium, mg/dL | 9.3±0.4 | 9.2±0.4 | 9.5±0.4 | 0.144 |
| LDL-C, mg/dL | 80 (63-96) | 80 (62-96) | 80 (71-100) | 0.45 |
| Triglyceride, mg/dL | 111 (78-171) | 113 (78-175) | 92 (77-124) | 0.40 |
| Glucose, mg/dL | 118 (108-132) | 120 (107-132) | 114 (110-127) | 0.71 |
| HbA1c, % | 6.2 (5.8-6.9) | 6.1 (5.8-6.8) | 6.8 (5.6-7.3) | 0.45 |
| IL-6, pg/mL | 3.0 (1.6-5.1) | 2.4 (1.3-3.6) | 4.6 (3.0-13.7) | 0.033 |
| TNF-α, pg/mL | 1.24 (0.90-1.56) | 1.14 (0.79-1.51) | 1.37 (0.97-2.07) | 0.34 |
| hs-CRP, ng/mL | 668 (375-1460) | 550 (279-1,390) | 920 (616-6,500) | 0.140 |
| Pentraxin 3, ng/mL | 1.96 (1.37-2.62) | 1.80 (1.31-2.25) | 2.63 (1.76-3.66) | 0.116 |
| VEGF >20 pg/mL, n (%) | 7 (23) | 6 (27) | 1 (13) | 0.40 |
| MCP-1, pg/mL | 188 (155-230) | 187 (153-211) | 234 (178-289) | 0.075 |
| Target lesion, n (%) | 0.46 | |||
| Left anterior descending artery | 19 (63) | 14 (64) | 5 (63) | |
| Left circumflex artery | 3 (10) | 3 (14) | 0 | |
| Right coronary artery | 8 (27) | 5 (23) | 3 (38) | |
| Balloon angioplasty, n (%) | 30 (100) | 22 (100) | 8 (100) | - |
| Stent implantation, n (%) | 17 (57) | 14 (64) | 3 (38) | 0.20 |
| Drug-coated balloon, n (%) | 13 (43) | 8 (36) | 5 (63) | 0.20 |
Continuous variables are presented as mean ± standard deviation if normally distributed and as median (interquartile range) if not normally distributed. Categorical variables are presented as the number of patients (%). CPRS, coronary plaque risk score; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CI, cerebral infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; IL-6, Interleukin-6; TNF-α, tumor necrosis factor-alpha; hs-CRP, high-sensitivity C-reactive protein; VEGF, vascular endothelial growth factor; MCP-1, monocyte chemoattractant protein-1.